Edmonton, Alberta-based startup Tevosol Inc. is hoping to make its mark in the growing warm perfusion organ transport market with a portable system for lungs that leverages a unique negative pressure ventilation technology. The company recently raised CAD$2 million (US$1.5 million) in seed financing to advance its Ex-Vivo Organ Support System (EVOSS) and is seeking a lead investor for a series A round to further product development and support clinical trials.
Chronic bronchitis affects more than 9 million people in the U.S., but current treatments fail to address the overproduction of mucus. Gala Therapeutics Inc., of Menlo Park, Calif., is looking to change that.
Seongnam, Korea-based Bridge Biotherapeutics Inc. nailed down a deal with Boehringer Ingelheim GmbH (BI) to develop the former's phase I autotaxin (ATX) inhibitor, BBT-877, for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).